Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5930 - Advanced Treatment Line (ATL) with Lenvatinib and Everolimus (Len+Eve) for Metastatic Renal Cell Carcinoma (mRCC); Analysis of a National Early Access Program (EAP).

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Renal Cell Cancer

Presenters

Avivit Peer

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

A. Peer1, M. Kolin1, K. Rouvinov2, D. Keizman3, D. Sarid4, R. Leibowitz-Amit5, R. Berger5, A. Sella6, A. Rasco6, E. Rosenbaum7, C. maurice-dror1, A. Neumann1, V. Neiman7

Author affiliations

  • 1 Oncology, Rambam Health Care Center, 31096 - Haifa/IL
  • 2 Oncology, Soroka University Medical Center, Beer Sheva/IL
  • 3 Oncology, Meir Medical Center, Kfar Saba/IL
  • 4 Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL
  • 5 Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 6 Oncology, Asaf Harofeh Medical Center, 70300 - Zerifin/IL
  • 7 Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 49100 - Petah Tikva/IL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5930

Background

VEGFR inhibition is a mainstay in the treatment of mRCC. In recent years third generation TKIs offer advantages in treatment efficacy while combinations further improve clinical activity. Treatment with Len+Eve is approved based on a randomized phase 2 study in the second line setting. Data on activity and efficacy of this combination as ATL beyond second line is limited. We aimed to report the activity of Len+Eve in mRCC patients (pts) treated per a national EAP.

Methods

Records from consecutive mRCC (pts) treated with Len+Eve in ATL per a national EAP in 7 centers, were retrospectively reviewed. We report the clinical benefit, progression free survival (PFS), overall survival (OS), and toxicity.

Results

Between 11/2016 – 12/2017, 39 mRCC pts were treated with Len+Eve. Median age 60 (39-82), male 72%. Majority of the pts (82%) underwent nephrectomy. Heng risk was good/intermediate/poor in 13% (n = 5)/41% (n = 16)/46% (n = 18). According to the treating physician, 69% (n = 27) of pts had high burden disease at treatment initiation. 13% (n = 5) were treated as second line, 51% (n = 20) as third and 36% (n = 14) as fourth line. All patients in the third and fourth line received prior immunotherapy. Clinical benefit (stable disease+ partial response) was 74% (54% partial response and 20% stable disease). Median PFS was 6 months (mos). After a median follow up time of 9 mos, 62% of the pts with a clinical benefit are still with a benefit and on treatment (range 5-16m). Most pts (72%, n = 28) are alive, with median OS not reached. Dose reduction was required in 49% of the patients due to mainly grade 3 toxicity. There were no treatment discontinuations due to toxicity.

Conclusions

Len+Eve as ATL in mRCC may benefit patients beyond second line treatment, and is associated with responses similar to those seen in a clinical trial setting in the ATL setting, with manageable toxicity.

Clinical trial identification

Legal entity responsible for the study

Avivit Peer.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.